Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty

Episode Summary

Executive Summary: Russ Roberts and Vinay Prasad argue that cancer drug markets are distorted by weak evidence standards, monopoly pricing, and incentives that reward marginal innovation over real breakthroughs. Prasad criticizes the FDA, insurers, academia, and careerism for sustaining a system that often subsidizes expensive drugs with limited benefit while ignoring more meaningful patient support and higher evidentiary bars.

Main Topics: Cancer drug innovation vs. pseudo-innovation (Priority: 5/5): Prasad argues the system fails to distinguish transformative drugs from marginal ones, allowing drugs with tiny survival gains to receive blockbuster status and monopoly pricing. FDA approval standards and evidentiary weakness (Priority: 5/5): He contends the FDA increasingly permits uncontrolled trials, weak control arms, and surrogate endpoints, which makes it easier for ineffective drugs to reach market and harder for better alternatives to compete. Drug pricing, insurance, and taxpayer subsidies (Priority: 5/5): The conversation emphasizes that public and private reimbursement effectively socializes the cost of marginal drugs, shifting burdens onto taxpayers while benefitting shareholders and manufacturers. Patient tradeoffs and quality of life (Priority: 4/5): Prasad and Roberts discuss how patients would often prefer cash, home help, or support services over expensive marginal-life-extension drugs, but current reimbursement hides those tradeoffs. Academic and regulatory capture (Priority: 4/5): Prasad says universities and the FDA are increasingly intertwined with pharma, weakening independence and discouraging criticism because careers, grants, and future jobs depend on industry relationships. Duty, courage, and professional ethics (Priority: 4/5): A major second theme is Prasad's broader moral critique: modern culture downplays duty in medicine, academia, and public life, replacing it with careerism, fear, and self-protection.

Key Arguments: Most new cancer drugs offer only small median survival gains, so the system over-rewards marginal advances and under-rewards genuinely transformational innovation. Uncontrolled studies and weak trial designs create uncertainty that benefits manufacturers, because unclear evidence makes approval easier and objections harder. FDA approval should require stronger comparison to real standards of care and more meaningful endpoints such as survival or quality of life. Taxpayer-funded reimbursement hides the true cost of marginal drugs, since patients do not directly confront the tradeoff between spending on medicine and spending on other forms of care or leaving money to family. Quality-of-life measures in trials may be misleading because drugs are often provided free in trials but are costly in real-world use, changing the actual patient experience. Academia has become too dependent on pharmaceutical funding, joint ventures, and future industry jobs, making open criticism risky and rare. The central moral failure is a loss of duty: professionals increasingly avoid hard choices, public responsibility, and discomfort even when others depend on them. Better patient-centered spending might prioritize home care, help with daily life, and convenience over slightly extending life with costly drugs. Raising the evidentiary bar could push companies to prune weak projects and focus R&D on meaningful breakthroughs rather than quantity of approvals. Current incentives may also crowd out or delay cheaper, nearly as effective alternatives by granting monopoly-like status to slightly newer drugs.

Data Points: Median survival improvement of a new cancer drug: 2.1 months - Prasad says this is the median improvement among consecutively approved new cancer drugs. Best example of transformational cancer drug: Gleevec (imatinib) - He cites it as the standout drug that turned chronic myeloid leukemia from a fatal disease into one with near-normal life expectancy. Original CML life expectancy before Gleevec: About 3 years - Prasad says a patient diagnosed in their 50s used to have roughly three years of life expectancy. Avastin annual cost: About $70,000 to $80,000 per year - He uses Avastin as an example of a costly drug offering only small survival gains. Alternative illustrative drug cost: $40,000 - Prasad asks whether a patient would rather take the drug or receive the money for home help or other needs. Copay burden mentioned in real-world care: $7,000 to $9,000 per year - He says quality-of-life in trials ignores that real patients may face substantial copays. Biden-era reduced copay burden mentioned: $1,000 to $2,000 per year - Prasad notes recent policy changes lowered some patient out-of-pocket costs. Sample uncontrolled approval study size: 60 patients - He describes a common approval pathway where a small single-arm study is used. Academic/public hiring signal: $100,000 more - He says oncology faculty could make roughly this much more in oncology departments than in epidemiology. Revolving-door career pattern: Majority of departing FDA medical reviewers - He states many leave FDA and go on to consult for pharma, citing a BMJ paper.

Pivotal Quotes: "We have dismantled the system that is meant to tell these two apart. Real innovation from pseudo innovation." — Vinay Prasad: His core critique of how drug development and reimbursement blur the line between breakthrough drugs and marginal ones. "The median improvement in survival of a new cancer drug coming on the market is 2.1 months." — Vinay Prasad: He uses this statistic to argue that most approved cancer drugs produce only modest benefit. "Our ancestors used to know what that word means, but in the modern world, it has fallen out of favor." — Vinay Prasad: He is describing duty as a lost moral ideal in medicine, academia, and public life.

Implications: The episode calls for stricter FDA standards, more honest pricing and reimbursement, and a cultural return to duty. For patients, it suggests spending should better reflect real-world value and not just incremental survival gains.